Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Guildford, UK: MedPharm Ltd (www.medpharm.co.uk), the topical drug development specialist, today announced it has been granted a series of further patents for its novel MedSpray® topical spray-on-film technology for dermatological, topical and transdermal drug delivery.
The North American drug delivery market is estimated to be worth in excess of $66.7 billion and is expected to register a CAGR of 8.9% between 2012 and 2017, transdermal/buccal systems are expected to make up a significant percentage of this figure . In addition, dermatological therapeutics in the top seven markets (US, UK, Germany, France, Italy, Spain, and Japan) are projected to grow to $19.1 billion by 2018 . Emerging markets are likely to increase the rate of market expansion further and MedSpray®, will help licensees take the lead in this expanding market.
MedSpray® is a novel transdermal and topical drug delivery tool that can be used to deliver drugs in extended release form via spray-on-films delivered to the skin or other mucosal (topical) membranes. MedSpray® offers many advantages over traditional drug delivery systems. The technology allows enhanced drug delivery into or across the skin/mucosal membranes by creating a film, which can be manipulated to suit the specific drug and disease. This results in a lack of first pass metabolism, improved toxicity profiles and the potential for sustained and targeted drug delivery To date, MedSpray® has been trialled with over 20 drugs up to and including clinical evaluation.
CEO Dr Andrew Muddle commented: “We now have patents for MedSpray® in key countries throughout Europe, North America, and the rest of the world including, Brazil, Russia, India and China. Widening our patent coverage will enable us to bolster the commercial use of the technology. Currently MedPharm has a number of licensees developing products with this technology and with these new patents, the company can continue to expand licenced products into new markets.”
“Our strategy is to work successfully with partners to develop new products with drugs provided by licensees,” continues Dr Muddle. “All such MedSpray® agreements are based upon payment of royalties and contract development fees to MedPharm.”
About the company:
MedPharm is a specialist pharmaceutical development company that is recognized internationally for its expertise in transdermal and topical (skin, nail, nose, lungs and other mucosal membranes) drug delivery systems and formulation. Established in 1999 and with numerous high profile customers, MedPharm has built a reputation for its unique and highly specialized service in contract research and development, together with expert project management. Projectsrange from simple feasibility tests, formulation and dosage design and optimization, through to preparation of GMP clinical supplies for Phase I/II trials with guaranteed subsequent smooth transfer through to commercial manufacturing sites. . The company operates a hybrid business model, with a CRO business and a development programme with a substantial patent portfolio of novel topical drug delivery systems. These systems include MedSpray®, MedNail®, MedTherm and, most recently AquaRMed. It has produced these innovations by exploiting itsinternal product development expertise, with a particular focus on dermatology. The company is actively seeking to license these technologies to third parties for developing their own compounds in non-competing indications. MedPharm’s laboratories in the UK are routinely inspected by Regulatory Authorities toensure that its Quality System meets the requirements for GMP and GLP.
MedPharm’s aim is to continue to build on its reputation as a specialist transdermal and topical pharmaceutical company concentrating on the development and commercial exploitation of specialist products for dermatology and other topical and transdermal indications.
More information can be found at www.medpharm.co.uk
Help employers find you! Check out all the jobs and post your resume.
